Neither Dysport nor Botox is categorically safer than the other. Both contain botulinum toxin type A, both carry the same FDA black box warning about the potential for toxin to spread beyond the injection site, and both have decades of clinical use supporting their safety profiles. The real differences come down to specific side effects, how much the product spreads in tissue, and a unique allergy concern with Dysport that doesn’t apply to Botox.
They Share the Same Black Box Warning
The FDA requires identical black box warnings on both Dysport and Botox. These warnings alert patients and providers that the effects of botulinum toxin can spread from the injection site to other parts of the body, potentially causing symptoms resembling botulism: difficulty swallowing, breathing problems, and muscle weakness far from where the injection was given. Both manufacturers are required to develop risk-management plans and provide medication guides to patients outlining these risks.
This warning exists for all botulinum toxin products on the market, not just these two. In practice, serious spread-related events are rare and tend to occur at the higher doses used for medical conditions like spasticity or cervical dystonia, not the smaller doses used for cosmetic treatments like frown lines.
Side Effect Rates Differ by Condition
When the two products have been compared head-to-head, some side effects show up more often with one than the other, depending on what’s being treated. In cervical dystonia (a condition causing involuntary neck muscle contractions), Dysport was associated with difficulty swallowing in about 26.8% of patients, compared to roughly 9 to 10.5% for Botox. That’s a meaningful difference for people being treated at the higher doses these conditions require.
For cosmetic use at lower doses, the side effect profiles are much more similar. Both commonly cause temporary bruising, mild headache, and occasional drooping at or near the injection site. Neither product has shown a consistent safety advantage over the other in the cosmetic setting.
Dysport Spreads More, but It May Not Matter
One of the longest-running safety debates between these two products involves how far they spread through tissue after injection. Dysport’s active molecule has a smaller protein complex (about 500 kilodaltons) compared to Botox’s larger complex (900 kilodaltons). Early research suggested this meant Dysport would diffuse more widely from the injection site, raising concerns about unintended muscle weakening nearby.
More recent evidence complicates that story. Studies comparing botulinum toxin products of very different molecular sizes, including one at 150 kilodaltons and another at 900, found no meaningful difference in how far they spread. Animal research has reached similar conclusions: protein size alone doesn’t reliably predict diffusion. So while Dysport’s greater spread was once considered a clear safety disadvantage, the current science suggests the difference is less significant than originally thought.
That said, the clinical perception of greater spread with Dysport persists, and many injectors account for it by adjusting their technique, placing injections slightly differently than they would with Botox.
Dosing Errors Are a Real Risk
One safety issue that’s unique to switching between these products is the dosing conversion. Dysport and Botox use completely different unit systems, and the units are not interchangeable. Getting an equivalent effect from Dysport requires roughly 2.5 to 3.5 times the number of units used for Botox. Clinical consensus has settled around a 3:1 ratio, meaning 60 units of Dysport for every 20 units of Botox.
A provider who doesn’t convert correctly can underdose (producing a weak result) or overdose (increasing the risk of side effects like excessive muscle weakness or spread to nearby muscles). This isn’t a flaw in either product itself, but it’s a practical safety concern any time someone switches from one to the other, or sees an injector who isn’t experienced with both.
Dysport Has a Unique Allergy Concern
Dysport’s formulation includes a component derived from cow’s milk protein. The FDA lists hypersensitivity to cow’s milk protein as a specific contraindication for Dysport. This means anyone with a known cow’s milk protein allergy should not receive Dysport. Botox does not contain this ingredient, so it doesn’t carry the same restriction.
This is a narrow but important distinction. Cow’s milk protein allergy is different from lactose intolerance. If you’re lactose intolerant, Dysport is not automatically off the table. But if you have a true immune-mediated allergy to milk protein, Botox would be the safer choice.
How to Think About “Safer”
For most people getting cosmetic injections, the safety profiles of Dysport and Botox are close enough that the choice comes down to personal preference, how your body responds, and your injector’s comfort level with each product. Neither is inherently dangerous, and neither is clearly safer across the board.
Where differences do emerge, they tend to favor Botox in specific scenarios: lower rates of swallowing difficulty at high medical doses, no milk protein allergy concern, and a longer track record with a wider range of FDA-approved uses. Dysport, for its part, was first approved in the U.S. in 2009 and now has approvals spanning cosmetic and medical indications including adult cervical dystonia, frown lines, and upper and lower limb spasticity in patients as young as two years old.
The most important safety factor isn’t which product you choose. It’s who injects it. An experienced provider who understands the dosing, spread characteristics, and anatomy relevant to your treatment will get safe results with either one.